{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:06:45Z","timestamp":1791173205219,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2004,10,6]],"date-time":"2004-10-06T00:00:00Z","timestamp":1097020800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1186\/bcr947","type":"journal-article","created":{"date-parts":[[2004,10,9]],"date-time":"2004-10-09T06:23:53Z","timestamp":1097303033000},"source":"Crossref","is-referenced-by-count":45,"title":["New targets for therapy in breast cancer: Farnesyltransferase inhibitors"],"prefix":"10.1186","volume":"6","author":[{"given":"Julia","family":"Head","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen RD","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,10,6]]},"reference":[{"key":"942_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/BF00694753","volume":"35","author":"GJ Clark","year":"1995","unstructured":"Clark GJ, Der CJ: Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat. 1995, 35: 133-144.","journal-title":"Breast Cancer Res Treat"},{"key":"942_CR2","first-page":"35","volume":"5","author":"P Norgaard","year":"1999","unstructured":"Norgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, et al: Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha\/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res. 1999, 5: 35-42.","journal-title":"Clin Cancer Res"},{"key":"942_CR3","first-page":"169","volume":"12","author":"GJ Clark","year":"1996","unstructured":"Clark GJ, Kinch MS, Gilmer TM, Burridge K, Der CJ: Overexpression of the Ras-related TC21\/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene. 1996, 12: 169-176.","journal-title":"Oncogene"},{"key":"942_CR4","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1074\/jbc.271.10.5289","volume":"271","author":"PJ Casey","year":"1996","unstructured":"Casey PJ, Seabra MC: Protein prenyltransferases. J Biol Chem. 1996, 271: 5289-5292. 10.1074\/jbc.271.10.5289.","journal-title":"J Biol Chem"},{"key":"942_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/383127a0","volume":"383","author":"CJ Marshall","year":"1996","unstructured":"Marshall CJ: Cell signalling; Raf gets it together. Nature. 1996, 383: 127-128. 10.1038\/383127a0.","journal-title":"Nature"},{"key":"942_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1101\/gad.11.6.701","volume":"11","author":"SG Kennedy","year":"1997","unstructured":"Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, Hay N: The PI3-kinase\/Akt sinaling pathway delivers an anti-apoptotic signal. Genes Dev. 1997, 11: 701-713.","journal-title":"Genes Dev"},{"key":"942_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1126\/science.8385802","volume":"260","author":"CA Lange-Carter","year":"1993","unstructured":"Lange-Carter CA, Pleiman CM, Gardner AM, Blumer KJ, Johnson GL: A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science. 1993, 260: 315-319.","journal-title":"Science"},{"key":"942_CR8","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.1073\/pnas.89.14.6403","volume":"89","author":"K Kato","year":"1992","unstructured":"Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ: Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA. 1992, 89: 6403-6407.","journal-title":"Proc Natl Acad Sci USA"},{"key":"942_CR9","first-page":"5302","volume":"55","author":"L Sepp-Lorenzino","year":"1995","unstructured":"Sepp-Lorenzino L, Ma Z, Rands E, Khol NE, Gibbs JB, Rosen NA: A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 1995, 55: 5302-5309.","journal-title":"Cancer Res"},{"key":"942_CR10","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/nm0895-792","volume":"1","author":"NE Khol","year":"1995","unstructured":"Khol NE, Omer CA, Conner MW, Anthony NJ, Davide JP, DeSolms SJ, Giuliani E, Gomez RP, Graham SL, Hamilton K, et al: Inhibition of farnesyltransferase induces regression of mammaruy and salivary carcinomas in ras transgenic mice. Nat Med. 1995, 1: 792-797. 10.1038\/nm0895-792.","journal-title":"Nat Med"},{"key":"942_CR11","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1016\/S0021-9258(18)99888-1","volume":"269","author":"Y Qian","year":"1994","unstructured":"Qian Y, Blaskovich MA, Saleem M, Seong CM, Wathen SP, Hamilton AD, Sebti SM: Design and structural requirements of potent peptidomimetics inhibitors of p21ras farnesyltransferase. J Biol Chem. 1994, 269: 12410-12413.","journal-title":"J Biol Chem"},{"key":"942_CR12","doi-asserted-by":"publisher","first-page":"30611","DOI":"10.1074\/jbc.270.51.30611","volume":"270","author":"WR Bishop","year":"1995","unstructured":"Bishop WR, Bond R, Petrin J, Wang L, Patton R, Doll R, Njoroge G, Catino J, Schwartz J, Windsor W, et al: Novel tricyclic inhibitors of farnesyl protein transferase. J Biol Chem. 1995, 270: 30611-30618. 10.1074\/jbc.270.51.30611.","journal-title":"J Biol Chem"},{"key":"942_CR13","first-page":"131","volume":"61","author":"DW End","year":"2001","unstructured":"End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, et al: Characterisation of the antitumor effects of the selective farnesyl protein transferase inhbitor R115777 in vivo and in vitro. Cancer Res. 2001, 61: 131-137.","journal-title":"Cancer Res"},{"key":"942_CR14","first-page":"72","volume":"6","author":"SRD Johnston","year":"2003","unstructured":"Johnston SRD: BMS-214662: a novel farnesyl transferase inhibitor. Curr Opin Invest Drugs. 2003, 6: 72-78.","journal-title":"Curr Opin Invest Drugs"},{"key":"942_CR15","first-page":"A597","volume":"18","author":"CD Britten","year":"1999","unstructured":"Britten CD, Rowinsky E, Yao S-L, Soignet S, Rosen N, Eckhardht SG, Drengler R, Hammond L, Siu LL, Smith L, et al: The farnesyl protein transferase (FTPase) inhibitor L-788,123 in patients with solid cancers [abstract]. Proc Am Soc Clin Oncol. 1999, 18: A597-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"942_CR16","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1128\/MCB.14.6.4193","volume":"14","author":"GC Prendergast","year":"1994","unstructured":"Prendergast GC, Davide JP, deSolms SJ, Giuliani E, Graham SL, Gibbs JB, Oliff A, Khol NE: Farnesylytransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of actin cytoskeleton. Mol Cell Biol. 1994, 14: 4193-4202.","journal-title":"Mol Cell Biol"},{"key":"942_CR17","first-page":"1846","volume":"57","author":"K Miquel","year":"1997","unstructured":"Miquel K, Pradines A, Sun J, Qian Y, Hamilton AD, Sebti SM, Favre G: GGTI-298 induces G0-G1 block and apoptosis wheras FTI-277 causes G2-M enrichment in A549 cells. Cancer Res. 1997, 57: 1846-1850.","journal-title":"Cancer Res"},{"key":"942_CR18","doi-asserted-by":"publisher","first-page":"20243","DOI":"10.1074\/jbc.273.32.20243","volume":"273","author":"L Sepp-Lorenzino","year":"1998","unstructured":"Sepp-Lorenzino L, Rosen N: A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild-type tumor cells. J Biol Chem. 1998, 273: 20243-20251. 10.1074\/jbc.273.32.20243.","journal-title":"J Biol Chem"},{"key":"942_CR19","first-page":"3544","volume":"7","author":"LR Kelland","year":"2001","unstructured":"Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End DW, Howes AJ, Dowsett M, Workman P, et al: Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res. 2001, 7: 3544-3550.","journal-title":"Clin Cancer Res"},{"key":"942_CR20","first-page":"4208","volume":"59","author":"W Du","year":"1999","unstructured":"Du W, Liu A, Prendergast GC: Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res. 1999, 59: 4208-4212.","journal-title":"Cancer Res"},{"key":"942_CR21","first-page":"F51","volume":"1333","author":"AD Cox","year":"1997","unstructured":"Cox AD, Der CJ: Farnesyltransferase inhibitors and cancer treatment: tageting simply ras?. Biochem Biophys Acta. 1997, 1333: F51-F71. 10.1016\/S0304-419X(97)00011-5.","journal-title":"Biochem Biophys Acta"},{"key":"942_CR22","doi-asserted-by":"publisher","first-page":"30451","DOI":"10.1074\/jbc.M003469200","volume":"39","author":"HR Ashar","year":"2000","unstructured":"Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, Kirschmeier P: Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 2000, 39: 30451-30457. 10.1074\/jbc.M003469200.","journal-title":"J Biol Chem"},{"key":"942_CR23","doi-asserted-by":"crossref","first-page":"14182","DOI":"10.1016\/S0021-9258(17)36772-8","volume":"269","author":"GL James","year":"1994","unstructured":"James GL, Goldstein JL, Pathak RK, Anderson RG, Brown MS: PxF, a prenylated protein of perioxsomes. J Biol Chem. 1994, 269: 14182-14190.","journal-title":"J Biol Chem"},{"key":"942_CR24","doi-asserted-by":"crossref","first-page":"20422","DOI":"10.1016\/S0021-9258(19)47079-8","volume":"264","author":"CC Farnsworth","year":"1989","unstructured":"Farnsworth CC, Wolda SL, Gelb MH, Glomset JA: Human lamin B contains a farnesylated cysteine residue. J Biol Chem. 1989, 264: 20422-20429.","journal-title":"J Biol Chem"},{"key":"942_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1128\/MCB.20.1.139-148.2000","volume":"20","author":"K Jiang","year":"2000","unstructured":"Jiang K, Coppola D, Crespo NC: The phosphoinositide 3-OH kinase\/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol. 2000, 20: 139-148.","journal-title":"Mol Cell Biol"},{"key":"942_CR26","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.1128\/MCB.20.16.6105-6113.2000","volume":"20","author":"A Liu","year":"2000","unstructured":"Liu A, Du W, Liu JP, Jessel TM, Prendergast GC: RhoB alteration is necessary for apoptotic and antineoplastic response to farnesyltransferase inhibitors. Mol Cell Biol. 2000, 20: 6105-6113. 10.1128\/MCB.20.16.6105-6113.2000.","journal-title":"Mol Cell Biol"},{"key":"942_CR27","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1358\/dof.2000.025.10.659165","volume":"25","author":"AA Adeji","year":"2000","unstructured":"Adeji AA: Protein farnesyl transferase as a target for the development of anticancer agents. Drugs Future. 2000, 25: 1069-1079.","journal-title":"Drugs Future"},{"key":"942_CR28","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1073\/pnas.95.4.1369","volume":"95","author":"MM Moasser","year":"1998","unstructured":"Moasser MM, Sepp-Lorenzino L, Khol NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen NA: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA. 1998, 95: 1369-1374. 10.1073\/pnas.95.4.1369.","journal-title":"Proc Natl Acad Sci USA"},{"key":"942_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s002800000170","volume":"46","author":"B Shi","year":"2000","unstructured":"Shi B, Yaremko B, Hajian G, Terracina G, Bishop WR, Liu M, Nielsen LJ: he farnesyl protein transferase inhibitor SCH66336 synergises with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol. 2000, 46: 387-393. 10.1007\/s002800000170.","journal-title":"Cancer Chemother Pharmacol"},{"key":"942_CR30","first-page":"523","volume":"40","author":"SG Skrazt","year":"1999","unstructured":"Skrazt SG, Bowden CR, End DW: Interaction of the farnesyly protein transferase inhibitor R115777 with cytotoxic chemotherapeutics in vitro and in vivo [abstract]. Proc Am Assoc Cancer Res. 1999, 40: 523-(A3447)","journal-title":"Proc Am Assoc Cancer Res"},{"key":"942_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1677\/erc.0.0060373","volume":"6","author":"RI Nicholson","year":"1999","unstructured":"Nicholson RI, McClelland RA, Robertson JRF, Gee JMW: Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer. 1999, 6: 373-387.","journal-title":"Endocr Relat Cancer"},{"key":"942_CR32","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/j.1460-2075.1996.tb00571.x","volume":"15","author":"G Bunone","year":"1996","unstructured":"Bunone G, Briand P, Miksicek R, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15: 2174-2183.","journal-title":"EMBO J"},{"key":"942_CR33","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/35035131","volume":"407","author":"T Simoncini","year":"2000","unstructured":"Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000, 407: 538-541. 10.1038\/35035131.","journal-title":"Nature"},{"key":"942_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S","volume":"95","author":"JMW Gee","year":"2001","unstructured":"Gee JMW, Robertson JFR, Ellis IO, Nicholson RI: Phosphorylation of erk 1\/2 mitogen activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer. 2001, 95: 247-254. 10.1002\/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S.","journal-title":"Int J Cancer"},{"key":"942_CR35","doi-asserted-by":"publisher","first-page":"30458","DOI":"10.1074\/jbc.M305226200","volume":"278","author":"L-A Martin","year":"2003","unstructured":"Martin L-A, Farmer I, Johnston SRD, Ali S, Marshall C, Dowsett M: Enhanced estrogen receptor (ER) aplha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long-term estrogen deprivation. J Biol Chem. 2003, 278: 30458-30468. 10.1074\/jbc.M305226200.","journal-title":"J Biol Chem"},{"key":"942_CR36","first-page":"5887","volume":"60","author":"H Kurokawa","year":"2000","unstructured":"Kurokawa H, Lenferink AEG, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL: Inhibition of HER2\/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000, 60: 5887-5894.","journal-title":"Cancer Res"},{"key":"942_CR37","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1210\/en.2003-0705","volume":"144","author":"JM Gee","year":"2003","unstructured":"Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jodan N, Wakeling AE, Nicholson RI: The anti-EGFR agent gefitinib (ZD 1839\/Iressa) improves anti-hormone response and prevents development of resistance in breast cancer in vitro. Endocrinology. 2003, 144: 5105-5117. 10.1210\/en.2003-0705.","journal-title":"Endocrinology"},{"key":"942_CR38","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jnci\/djh166","volume":"96","author":"J Shou","year":"2004","unstructured":"Shou J, Massaraweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer. J Natl Cancer Inst. 2004, 96: 926-935. 10.1093\/jnci\/djh166.","journal-title":"J Natl Cancer Inst"},{"key":"942_CR39","doi-asserted-by":"publisher","first-page":"346s","DOI":"10.1158\/1078-0432.CCR-031206","volume":"10","author":"RI Nicholson","year":"2004","unstructured":"Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JMW: Nonendocrine pathways and endocrine resistance; observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res. 2004, 10: 346s-354s.","journal-title":"Clin Cancer Res"},{"key":"942_CR40","doi-asserted-by":"publisher","first-page":"A245","DOI":"10.1023\/A:1020820103126","volume":"76","author":"SRD Johnston","year":"2002","unstructured":"Johnston SRD, Head J, Valenti M, Detre S, Dowsett M: Endocrine therapy combined with the farnesyltransferase inhibitor R115777 produces enhanced tumour growth inhibition in hormone-sensitive MCF-7 human breast cancer xenografts in-vivo [abstract]. Breast Cancer Res Treat. 2002, 76: A245-10.1023\/A:1020820103126.","journal-title":"Breast Cancer Res Treat"},{"key":"942_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1023\/A:1022105511409","volume":"78","author":"CA Ellis","year":"2003","unstructured":"Ellis CA, Vos MD, Wickline M, Riley C, Vallecorsa T, Telford WG, Zujewski J, Clark GJ: Tamoxifen and the farnesyl transferase inhibitor FTI-2777 synergise to inhibit growth in estrogen receptor positive breast tumor cell lines. Breast Cancer Res Treat. 2003, 78: 59-67. 10.1023\/A:1022105511409.","journal-title":"Breast Cancer Res Treat"},{"key":"942_CR42","first-page":"A3868","volume":"45","author":"BJ Long","year":"2004","unstructured":"Long BJ, Liu G, Marrinan CH, Maxwell E, Black S, Gheyas F, Nomeir A, Liu M, Kirschmeier P, Bishop R: Combining the farnesyl transferase inhibitor (FTI) Lonafarnib (SCH66336) with antiestrogens and aromatase inhibitors results in enhanced growth inhibition of hormone-dependent human breast cancer cells and tumor xenografts [abstract]. Proc Am Assoc Cancer Res. 2004, 45: A3868-","journal-title":"Proc Am Assoc Cancer Res"},{"key":"942_CR43","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ijc.11263","volume":"106","author":"SF Doisneau-Sixou","year":"2003","unstructured":"Doisneau-Sixou SF, Cestac P, Faye J-C, Favre G, Sutherland RL: Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell cycle progression. Int J Cancer. 2003, 106: 789-798. 10.1002\/ijc.11263.","journal-title":"Int J Cancer"},{"key":"942_CR44","first-page":"A502","volume":"21","author":"D Cunningham","year":"2002","unstructured":"Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, Kurteva G, Iveson T, Andre T, Dostalova J, Illes A, Jia X, Palmer P: Randomized double-blind placebo controlled trial of the farnesyltransferase inhibitor R-115777 (Zarnestra) in advanced refractory colorectal cancer. Proc Am Soc Clin Oncol. 2002, 21: A502-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"942_CR45","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","volume":"22","author":"E Van Cutsem","year":"2004","unstructured":"Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, et al: Phase III Trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer (PC). J Clin Oncol. 2004, 22: 1430-1438. 10.1200\/JCO.2004.10.112.","journal-title":"J Clin Oncol"},{"key":"942_CR46","first-page":"747","volume":"9","author":"RB Lobell","year":"2002","unstructured":"Lobell RB, Liu D, Buser CA, Davide JP, DePuy E, Hamilton K, Koblan KS, Lee Y, Mosser S, Motzel SL, et al: Preclinical and clinical pharmacodynamic assessment of L-788,123, a dual inhibitor of farnesyl protein transferase and geranylgeranyl protein transferase-type-1. Mol Cancer Ther. 2002, 9: 747-758.","journal-title":"Mol Cancer Ther"},{"key":"942_CR47","first-page":"1871","volume":"60","author":"AA Adjei","year":"2000","unstructured":"Adjei AA, Erlichman C, Davis JD, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop R, et al: A phase I trial of the farnesyl transferase inhibitor SCH66336; evidence for biological and clinical activity. Cancer Res. 2000, 60: 1871-1877.","journal-title":"Cancer Res"},{"key":"942_CR48","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2001.19.4.1167","volume":"19","author":"F Eskens","year":"2001","unstructured":"Eskens F, Awada A, Cutler DL, deJonge MJA, Luyten GPM, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske A, et al: Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily in patients with advanced solid tumors. J Clin Oncol. 2001, 19: 1167-1175.","journal-title":"J Clin Oncol"},{"key":"942_CR49","first-page":"A601","volume":"18","author":"G Hudes","year":"1999","unstructured":"Hudes G, Schol J, Baab J, Rogatko , Bol C, Horak I, Langer C, Goldstein LJ, Szarka C, Meropol NJ, Weiner L: Phase I clinical and pharmacokinetic trial of the farnesylytransferase inhibitor R115777 on a 21-day dosing schedule [abstract]. Proc Am Soc Clin Oncol. 1999, 18: A601-","journal-title":"Proc Am Soc Clin Oncol"},{"key":"942_CR50","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2003.10.064","volume":"21","author":"SRD Johnston","year":"2003","unstructured":"Johnston SRD, Hickish T, Ellis PA, Houston S, Kelland LR, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer PA, et al: Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyltransferase inhibitor R115777 (Zarnestra) in patients with advanced breast cancer. J Clin Oncol. 2003, 21: 2492-2499. 10.1200\/JCO.2003.10.064.","journal-title":"J Clin Oncol"},{"key":"942_CR51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1517\/14728214.8.1.163","volume":"8","author":"J Head","year":"2003","unstructured":"Head J, Johnston SRD: Protein farnesyltransferase inhibitors. Expert Opin Emerg Drugs. 2003, 8: 163-178. 10.1517\/eoed.8.1.163.21041.","journal-title":"Expert Opin Emerg Drugs"},{"key":"942_CR52","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1158\/1078-0432.CCR-03-0412","volume":"10","author":"F Khuri","year":"2004","unstructured":"Khuri F, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, et al: Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxele in solid tumours. Clin Cancer Res. 2004, 10: 2968-2976.","journal-title":"Clin Cancer Res"},{"key":"942_CR53","first-page":"80a","volume":"20","author":"MJ Piccart","year":"2001","unstructured":"Piccart MJ, Branie F, de Valeriola D, Dubuisson M, Hennebert P, Gil T, Forget F, Seifert W, Thibault A, Bol C, et al: A phase I clinical and pharmacokinetic trial of the farnesyl transferase inhibitor R115777 + docetaxel; a promising combination in patients with solid tumours [abstract]. Proc Am Soc Clin Oncol. 2001, 20: 80a-(A318)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"942_CR54","first-page":"80a","volume":"20","author":"SN Holden","year":"2001","unstructured":"Holden SN, Eckhardht S, Fisher S, Persky M, Mikule C, O'Bryant CL, Morrow M, Richards H, Rodriquez S, Bol C, et al: A phase I pharmacokinetic and biological study of the farnesyl transferase inhibitor R115777 and capecitabine in patients with advanced solid malignancies [abstract]. Proc Am Soc Clin Oncol. 2001, 20: 80a-(A316)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"942_CR55","first-page":"37","volume":"23","author":"PF Lebowitz","year":"2004","unstructured":"Lebowitz PF, Eng-Wong J, Balis F, Widemann B, Jayaprakash N, Gantz S, Chow C, Merino M, Zujewski J: A phase I trial of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in hormone-receptor positive metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol. 2004, 23: 37-(A644)","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr947.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/bcr947\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr947.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:00:01Z","timestamp":1624698001000},"score":1,"resource":{"primary":{"URL":"http:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/bcr947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["942"],"URL":"https:\/\/doi.org\/10.1186\/bcr947","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,6]]},"article-number":"262"}}